Pregnancy: Animal studies are insufficient with respect to reproductive toxicity and teratogenicity (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Administration of phenylephrine in late pregnancy or labour may potentially cause fetal hypoxia and bradycardia. Use of injectable phenylephrine is possible during pregnancy in accordance with the indications.
The combination with some oxytocic agents can cause severe hypertension (see Interactions).
Breast-feeding: Small quantities of phenylephrine are excreted in human breast milk and oral bioavailability may be low.
Administering vasoconstrictors to the mother exposes the infant to a theoretical risk of cardiovascular and neurological effects. However, in the event of a single bolus administration during childbirth, breast-feeding is possible.
Fertility: There is no available data concerning fertility after exposure to phenylephrine (see Pharmacology: Toxicology: Preclinical safety data under Actions).